1834 / 1851
Toxicity of concurrent SRT and
ALK-inhibitors
crizotinib, ceritinib, alectinib
available data
does not allow for a robust
conclusion
on safety of combined crizotinib,
ceritinib, alectinib and SRT.
Kroeze S et al. Cancer Treatment Reviews 53 (2017) 25–37